Celldex discontinues late-stage study of brain cancer vaccine

Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant difference in survival rates compared with chemotherapy.Reuters | March 08, 2016, 09:11 IST

The company's shares plummeted about 60 percent to $3.28 in premarket trading on Monday.

The vaccine, Rintega, is designed to target a specific genetic mutation seen in about 30 percent of glioblastoma multiforme (GBM) tumors.

After a preplanned interim analysis, the independent data safety and monitoring board estimated that overall survival of patients with newly-diagnosed GBM who were given Rintega was at a par with those in the control group.

Based on the board's recommendation, Celldex is abandoning the study, it said, adding that it did not expect to incur substantial additional costs related to Rintega. (Reporting by Natalie Grover in Bengaluru; Editing by Kirti Pandey)

With immense pride “India Live” celebrated its 10th national conference in Mumbai from 28th February to 3rd March 2019. The conference turned out to be a gold mine of information, with emphasis on academics, education and exchange of knowledge with leaders in interventional cardiology from both India and abroad.